Note : These are sick Patients not healthy volunteers
Number of subjects : 1440 (18-64)
960 (65 over) elderly
Total: 2400 subjects
A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to 104 Weeks Dosing, Placebo- Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain(BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)
The clock is ticking ... Stock
